Quizartinib, a type II FLT3i selective for FLT3-ITD, received FDA approval in July 2023 as a frontline treatment for FLT3-ITD AML in combination with “7 + 3” induction, following a consolidation regimen in combination with cytarabine, and as maintenance monotherapy after consolidation (excluding maintenance post allogeneic orthotopic transplantation (allo-OT)). This evidence concerns the gene FLT3 and acute myeloid leukemia.